JP2001524941A - 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物 - Google Patents

可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物

Info

Publication number
JP2001524941A
JP2001524941A JP53119198A JP53119198A JP2001524941A JP 2001524941 A JP2001524941 A JP 2001524941A JP 53119198 A JP53119198 A JP 53119198A JP 53119198 A JP53119198 A JP 53119198A JP 2001524941 A JP2001524941 A JP 2001524941A
Authority
JP
Japan
Prior art keywords
precipitate
soluble
extracellular
therapeutic agent
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53119198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001524941A5 (cg-RX-API-DMAC10.html
Inventor
サミュエル・ローズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2001524941A publication Critical patent/JP2001524941A/ja
Publication of JP2001524941A5 publication Critical patent/JP2001524941A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP53119198A 1997-01-13 1998-01-13 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物 Pending JP2001524941A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/782,219 US6080383A (en) 1997-01-13 1997-01-13 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US08/782,219 1997-01-13
PCT/US1998/000511 WO1998030247A1 (en) 1997-01-13 1998-01-13 A method and composition for cancer treatment by enzymatic conversion of soluble radioactive toxic agents

Publications (2)

Publication Number Publication Date
JP2001524941A true JP2001524941A (ja) 2001-12-04
JP2001524941A5 JP2001524941A5 (cg-RX-API-DMAC10.html) 2005-09-08

Family

ID=25125383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53119198A Pending JP2001524941A (ja) 1997-01-13 1998-01-13 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物

Country Status (5)

Country Link
US (2) US6080383A (cg-RX-API-DMAC10.html)
EP (1) EP1047456A4 (cg-RX-API-DMAC10.html)
JP (1) JP2001524941A (cg-RX-API-DMAC10.html)
AU (1) AU5913198A (cg-RX-API-DMAC10.html)
WO (1) WO1998030247A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068382A1 (en) * 1999-05-18 2003-04-10 Samuel Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US7807136B2 (en) * 1997-01-13 2010-10-05 David S. Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
AU755706B2 (en) * 1998-03-20 2002-12-19 Genzyme Corporation Methods to provoke anti-cancer immune responses
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
JP2004525109A (ja) * 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6565537B2 (en) * 2001-04-18 2003-05-20 Dennis R. Tollini Tube securing assembly
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030175337A1 (en) * 2001-10-29 2003-09-18 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US7615221B2 (en) * 2004-07-23 2009-11-10 Oncologic, Inc. Compositions and methods for treating cancer
WO2021016548A1 (en) 2019-07-25 2021-01-28 North Carolina State University Polyiodide binding compounds and methods of use thereof
EP4054561A4 (en) 2019-11-08 2023-12-20 North Carolina State University Cross-linking compounds and methods of use thereof
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189470A (en) * 1973-01-30 1980-02-19 Bio-Response, Inc. Method for the continuous removal of a specific antibody from the lymph fluid in animals and humans
US3964467A (en) * 1973-01-30 1976-06-22 Bio Response Inc. Methods and apparatus for augmentation of the production of anti-bodies in animals and humans and the collection thereof
CA1041445A (en) * 1973-04-09 1978-10-31 Sam Rose Method and apparatus for continuous mass in vitro suspension culture of cells
EP0109861A3 (en) * 1982-11-23 1986-05-14 Bio-Response Inc. Method for isolating cells
IN165717B (cg-RX-API-DMAC10.html) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
US6080383A (en) 2000-06-27
WO1998030247A1 (en) 1998-07-16
US20020022003A1 (en) 2002-02-21
EP1047456A4 (en) 2004-06-16
EP1047456A1 (en) 2000-11-02
US6468503B2 (en) 2002-10-22
AU5913198A (en) 1998-08-03

Similar Documents

Publication Publication Date Title
Wu et al. Metal-free bioorthogonal click chemistry in cancer theranostics
US6468503B2 (en) Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
JPH03503898A (ja) 薬剤輸送系に関する更なる改良
US5182107A (en) Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
JP2005501011A (ja) 組織特異的内皮膜タンパク質
JP2002518460A (ja) プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
IL91933A (en) Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues
JPH02503088A (ja) 抗体フラグメント複合体の調製方法
JPH05502880A (ja) トランスロケーション領域および細胞結合領域を有するハイブリッド分子
JP2008535475A (ja) Q3sparc欠失変異体及びその使用
US20110142756A1 (en) Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer
CN120590505B (zh) 一种重组补体蛋白及在制备抗白血病药物中的应用
JPH05503933A (ja) 化合物
CA2323210C (en) Enhancement of intracellular delivery and tissue targeting of drugs and genes
US20180044635A1 (en) Surface-modified macrophages for cell-based delivery
EP1809332B1 (en) Compositions for multi-step delivery of hot-spots radiation to cancer cells
US6602988B2 (en) Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects
WO2024017192A1 (zh) 包含血细胞的药物递送系统
US20030068382A1 (en) Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
KR20250074798A (ko) 종양에 반응하는 탄소 양자점을 이용한 암 치료 및 진단용 경구투여형 유전자 전달체 및 이의 제조 방법
EP0485749A2 (en) Chemical modification of antibodies for creating of immunoconjugates
Koumarianou et al. Development of a novel bi-specific monoclonal antibody approach for tumour targeting
Denmeade Targeting Mitochondrial Inhibitors for Metastatic Castrate-Resistant Prostate Cancer
JP2007001923A (ja) N−アセチルグルコサミン糖鎖認識タンパク質
CN121466317A (zh) 一种时空级联型抗体偶联药物及其制备方法与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081111